Experimental gene therapy found to slow Huntington’s disease progression, company says

Drugmaker uniQure announced that its experimental gene therapy, AMT-130, demonstrated a 75% slowing of Huntington’s disease progression over 36 months in high-dose patients during a pivotal Phase 1/2 study, alongside a manageable safety profile. This represents a significant advancement toward a potential first genetic treatment for the rare neurological disorder, with the company targeting FDA submission in Q1 2026 and a possible launch by late 2026, despite some expert observations on the early-stage trial design.

Analysis

UniQure (QURE) reported highly positive top-line data from its pivotal Phase 1/2 study of AMT-130, a gene therapy for Huntington’s disease. Patients receiving a high dose of the therapy demonstrated a 75% slowing in disease progression over a 36-month period, supported by an 8.2% reduction in the neurodegeneration biomarker neurofilament light protein. The treatment's safety profile was described as "manageable," with adverse events primarily related to the surgical administration and subsequently resolved. These results position AMT-130 as a potential first-in-class genetic treatment for a rare disease with no curative options, creating a significant market opportunity. However, investors should note several caveats highlighted by external experts: the study involved a modest 29 patients, lacked a placebo-controlled arm (using natural history data for comparison), and the full data has not yet been peer-reviewed. The company has outlined a clear regulatory pathway, targeting an FDA submission in Q1 2026, which sets a long-term catalyst but also underscores the extended timeline and inherent regulatory risk before potential commercialization.

Key Decisions for Investors

• Given the strong efficacy signal and first-mover potential in a high-unmet-need indication, investors with a long-term horizon and high risk tolerance may view this as a significant, albeit early-stage, value inflection point for uniQure.
• It is critical to scrutinize the full, peer-reviewed data upon publication to validate the reported efficacy, paying close attention to the statistical rigor given the small patient cohort and the use of a non-placebo control group.
• Investors should model the extended timeline to commercialization, with key catalysts being the FDA submission targeted for Q1 2026 and subsequent regulatory milestones, while monitoring for any competitor progress in the Huntington's disease space.